Gaudium IVF and Women Health Ltd

Gaudium IVF and Women Health Limited has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal codes. The trading window will remain shut from July 1, 2026, until 48 hours after the announcement of the unaudited standalone and consolidated financial results for the quarter ending June 30, 2026. The date for the board meeting to approve these results will be communicated separately.

Gaudium IVF and Women Health Ltd has submitted a corrigendum to its consolidated financial results for the quarter and year ended March 31, 2026. The correction addresses inadvertent regrouping and typographical errors in comparative figures for the previous financial year ended March 31, 2025, specifically within the Consolidated Balance Sheet and Statement of Profit and Loss. The company clarifies that standalone results were accurate, and the overall figures for March 31, 2026, remain unchanged. The errors are clerical and do not impact the Profit After Tax, Net Worth, or overall financial position for the current period. The statutory auditors have confirmed the rectifications are limited to comparative figures and do not necessitate updating their report.

Gaudium IVF and Women Health Ltd announced its Board of Directors has approved the establishment of a new Gaudium Women Hospital in Lucknow, Uttar Pradesh. The hospital will be set up through a long-term lease arrangement with the property owner, Mrs. Abhilasha Singh and M/s. Abhilasha Enterprises. The estimated project cost for development, construction, and equipping the hospital is up to ₹15 crore. The lease agreement is for 30 years, with a 15-year lock-in period. Gaudium IVF will pay the landowner 10% of net revenue generated from the hospital, plus applicable taxes, after recovering an initial security deposit of ₹3 crore. The company will manage the hospital operations during the lease tenure. The parties involved are not related to the promoter or group companies.

Gaudium IVF and Women Health Limited announced its audited financial results for Q4 and the full financial year ended March 31, 2026. For Q4 FY26, revenue from operations grew 12.74% YoY to ₹30.35 Cr, EBITDA increased 39.56% YoY to ₹12.17 Cr with a 40.10% margin, and PAT rose 29.46% YoY to ₹8.36 Cr with a 27.54% margin. For the full FY26, revenue surged 47.56% YoY to ₹104.35 Cr, EBITDA grew 31.69% YoY to ₹37.70 Cr (36.13% margin), and PAT increased 27.69% YoY to ₹24.48 Cr (23.47% margin). The growth was driven by higher patient volumes, clinical success rates, and operating leverage. The company also integrated AI-led embryology in April 2026 and plans to operationalize 3 new IVF hubs soon.

Gaudium IVF and Women Health Limited's Board of Directors, at its meeting on May 28, 2026, approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. The results include an unmodified auditor's report issued by S K G N & Associates LLP, in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The trading window for designated persons and their immediate relatives remains closed until May 30, 2026.

Gaudium IVF and Women Health Limited's Board of Directors, at its meeting on May 28, 2026, approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. The results were accompanied by an unmodified auditor's report issued by S K G N & Associates LLP, the company's Statutory Auditors. In compliance with SEBI regulations, the trading window for designated persons and their immediate relatives remains closed up to and including May 30, 2026. The disclosure will also be hosted on the company's website.

The National Company Law Tribunal (NCLT), New Delhi Bench, has rejected the insolvency petition filed by Ramaa Capital against Gaudium IVF and Women Health Limited. The petition, filed under Section 9 of the Insolvency and Bankruptcy Code, 2016, was dismissed by the NCLT on May 15, 2026. Gaudium IVF received the order copy on May 22, 2026, and has disclosed the information as per SEBI regulations. The company states that the NCLT's decision has no impact on its financial or operational activities.

Gaudium IVF and Women Health Ltd has scheduled a Board of Directors meeting on May 28, 2026, to consider and approve the audited standalone and consolidated financial statements/results for the quarter and year ended March 31, 2026. The board will also review the auditor’s report. The trading window for dealing in the company's securities has been closed from April 1, 2026, and will remain closed until 48 hours after the declaration of the results.

Gaudium IVF and Women Health Ltd has released the Monitoring Agency Report for the quarter ended March 31, 2026, as per SEBI regulations. The report, issued by Infomerics Valuation and Rating Limited, confirms no deviations from the objects of the IPO proceeds utilization. The full report is available on the company's website.

Gaudium IVF and Women Health Ltd responded to a BSE query regarding significant share price movement. The company informed that it has disclosed all material events and information to the stock exchanges in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It confirmed that there is no undisclosed price-sensitive information or any impending announcement/corporate action that could explain the recent price or volume behavior in its shares. The company stated that the increase or decrease in its share price is purely market-driven and assured continued prompt disclosure of all material events/information/actions.